Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 11, 2020Thoracic CancerOpen Access

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)

View Full Paper
Ask AI
Bookmark
Share

Authors

WKWanhai KeLZLi ZhangYDYan Dai

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ke et al. (2020) studied this question.

synapsesocial.com/papers/6aac90ceb4cbfccb9d20df47https://doi.org/10.1111/1759-7714.13341
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interleukin‐6 and its receptor in cancer2007 · 368 citations
  2. 2Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer2011 · 332 citations
  3. 3A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer2011 · 247 citations
  4. 4Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade2017 · 332 citations
  5. 5Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018 · 88,284 citations